International Journal of Science and Research (IJSR)

International Journal of Science and Research (IJSR)
Call for Papers | Fully Refereed | Open Access | Double Blind Peer Reviewed

ISSN: 2319-7064


Downloads: 2 | Views: 24 | Weekly Hits: ⮙2 | Monthly Hits: ⮙2

Comparative Studies | Health and Medical Sciences | Somalia | Volume 13 Issue 2, February 2024


The Impact of COVID-19 on Measles-Containing Vaccines (MCV1 and MCV2) Utilization in Benadir Region, Somalia

Abdirahman Omar Abdi [2]


Abstract: This study aims to examine the impact of the COVID-19 pandemic on the utilization of Measles-Containing Vaccines 1 (MCV1) and 2 (MCV2) in the Benadir Region of Somalia. The COVID-19 pandemic has disrupted healthcare systems worldwide, and routine immunization programs have been particularly affected. Understanding the effects of the pandemic on vaccine utilization is crucial for devising strategies to mitigate potential outbreaks of vaccine-preventable diseases. Preliminary findings indicate a substantial decline in MCV1 and MCV2 utilization during the COVID-19 pandemic. The number of vaccinations administered during the pandemic period (2020-2021) was significantly lower compared to the pre-pandemic period (2019). The decline in vaccine utilization can be attributed to various factors, including disruptions in healthcare services, fear of visiting health facilities, and resource reallocation to COVID-19 response efforts. Moreover, routine immunization programs play a crucial role in preventing these diseases, and a decrease in vaccine utilization can lead to a loss of herd immunity and subsequent outbreaks. It is essential to address the barriers to vaccination and implement strategies to restore and strengthen routine immunization services.


Keywords: COVID-19, Impact, MCV1, MCV2, utilization, Benadir Region, Somalia


Edition: Volume 13 Issue 2, February 2024,


Pages: 225 - 230


How to Download this Article?

Type Your Valid Email Address below to Receive the Article PDF Link


Verification Code will appear in 2 Seconds ... Wait

Top